Consequently, when CTLA-4 inhibitor was applied, CD4+T-cell proliferative capacity was enhanced, and the Treg/CD4+ T ratio was lowered although Treg numbers were not affected, which restored T-cell functional defects and produced stronger anti-tumor response in vitro. The gene discussed is CD4; the disease is neoplasm.